Search

Home > GRACEcast Lung Cancer Video > Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Podcast: GRACEcast Lung Cancer Video
Episode:

Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Category: Science & Medicine
Duration: 00:04:14
Publish Date: 2015-11-14 14:00:00
Description:

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Total Play: 0